CN114621227A - 一种盐酸伐昔洛韦、制剂及其制备方法 - Google Patents
一种盐酸伐昔洛韦、制剂及其制备方法 Download PDFInfo
- Publication number
- CN114621227A CN114621227A CN202210189997.4A CN202210189997A CN114621227A CN 114621227 A CN114621227 A CN 114621227A CN 202210189997 A CN202210189997 A CN 202210189997A CN 114621227 A CN114621227 A CN 114621227A
- Authority
- CN
- China
- Prior art keywords
- valacyclovir hydrochloride
- hydrochloride
- preparation
- valacyclovir
- collecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZCDDBUOENGJMLV-QRPNPIFTSA-N Valacyclovir hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 ZCDDBUOENGJMLV-QRPNPIFTSA-N 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 229940064636 valacyclovir hydrochloride Drugs 0.000 claims abstract description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 27
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960004150 aciclovir Drugs 0.000 claims abstract description 24
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 20
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims abstract description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims abstract description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000007787 solid Substances 0.000 claims abstract description 15
- 238000001035 drying Methods 0.000 claims abstract description 14
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000000047 product Substances 0.000 claims abstract description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 8
- CANZBRDGRHNSGZ-NSHDSACASA-N (2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 CANZBRDGRHNSGZ-NSHDSACASA-N 0.000 claims abstract description 7
- 239000003480 eluent Substances 0.000 claims abstract description 7
- 230000003197 catalytic effect Effects 0.000 claims abstract description 5
- 238000007327 hydrogenolysis reaction Methods 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 5
- -1 Pd-C377 Substances 0.000 claims abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 28
- 238000007873 sieving Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229920000881 Modified starch Polymers 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 239000000377 silicon dioxide Substances 0.000 claims description 14
- 235000012239 silicon dioxide Nutrition 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 11
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims description 3
- 238000009501 film coating Methods 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000011812 mixed powder Substances 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 238000004237 preparative chromatography Methods 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 239000012535 impurity Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010812 external standard method Methods 0.000 description 3
- 239000012088 reference solution Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 229940093257 valacyclovir Drugs 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- TUWDPWSZHGLVHH-UHFFFAOYSA-N (4,6-dimethoxy-1,3,5-triazin-2-yl)-(methoxymethyl)cyanamide Chemical compound COCN(C#N)C1=NC(OC)=NC(OC)=N1 TUWDPWSZHGLVHH-UHFFFAOYSA-N 0.000 description 1
- HXKKMVNECDENPT-UHFFFAOYSA-N 2-amino-9-(2-hydroxyethoxymethyl)-3h-purin-6-one;hydrochloride Chemical compound Cl.N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 HXKKMVNECDENPT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PGSPUKDWUHBDKJ-UHFFFAOYSA-N 6,7-dihydro-3h-purin-2-amine Chemical compound C1NC(N)=NC2=C1NC=N2 PGSPUKDWUHBDKJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- AYWLSIKEOSXJLA-UHFFFAOYSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=N2 AYWLSIKEOSXJLA-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种盐酸伐昔洛韦、制剂及其制备方法,所述盐酸伐昔洛的制备方法包括以下步骤:(1)将阿昔洛韦与N‑苄氧羰基‑L‑缬氨酸、4‑二甲胺基吡啶、N,N'‑二环己基碳酰亚胺反应得到产物,过滤,收集滤液减压浓缩后得黄色油状物,采用洗脱剂过柱,所述洗脱剂由正己烷和乙酸乙酯组成,收集白色固体;(2)将白色固体与Pd–C377、甲醇、四氢呋喃和盐酸溶液,置高压釜中,催化氢解,过滤,收集滤液,经减压浓缩后,再经制备型层析柱制备,收集纯化液,减压干燥,得白色粉末状固体,即得盐酸伐昔洛韦。采用本发明盐酸伐昔洛韦制备盐酸伐昔洛韦片和盐酸伐昔洛韦胶囊,得到产品质量高。
Description
技术领域
本发明涉及药物领域,特别涉及一种盐酸伐昔洛韦、制剂及其制备方法。
背景技术
盐酸伐昔洛韦片,盐酸伐昔洛韦为主药,其分子式:C13H21ClN6O4;分子量:360.79。盐酸伐昔洛韦是伐昔洛韦的盐酸盐,伐昔洛韦是阿昔洛韦-L-缬氨酸酯的前体。本品是阿昔洛韦的前体药物,口服后吸收迅速并在体内很快转化为阿昔洛韦,其抗病毒作用为阿昔洛韦所发挥,药物被磷酸化成活化型无环鸟苷三磷酸酯,与脱氧核苷竞争病毒胸腺嘧啶激酶或细胞激酶,与脱氧鸟嘌呤三磷酸酯竞争病毒DNA多聚酶,从而抑制了病毒DNA合成,显示抗病毒作用。其在临床上现已作为疱疹、带状疱疹等的治疗药物在全世界广泛使用。伐昔洛韦对于抗病毒治疗的药效会比阿昔洛韦要好一些,它的利用度是阿昔洛韦的三到五倍。现有方法以阿昔洛韦为起始原料,与受保护的L-缬氨酸缩合,然后脱保护基,再成盐,共3步反应制得。现有方法,盐酸伐昔洛韦收率低,阿昔洛韦残留多,杂质含量高,不利于提高药品质量。
发明内容
鉴于此,本发明提出一种盐酸伐昔洛韦、制剂及其制备方法,解决上述问题。
本发明的技术方案是这样实现的:一种盐酸伐昔洛韦的制备方法,包括以下步骤:(1)将阿昔洛韦与N-苄氧羰基-L-缬氨酸、4-二甲胺基吡啶(DMAP)、N,N'-二环己基碳酰亚胺(DCC)反应得到产物,过滤,收集滤液减压浓缩后得黄色油状物,采用洗脱剂过柱,所述洗脱剂由正己烷和乙酸乙酯组成,收集白色固体;
(2)将白色固体与Pd–C377、甲醇、四氢呋喃(THF)和盐酸溶液,置高压釜中,催化氢解,过滤,收集滤液,经减压浓缩后,再经制备型层析柱制备,流动相为甲醇和水,收集纯化液,减压干燥,得白色粉末状固体,即得盐酸伐昔洛韦。
进一步的,所述阿昔洛韦与N-苄氧羰基-L-缬氨酸、4-二甲胺基吡啶(DMAP)、N,N'-二环己基碳酰亚胺(DCC)的质量比为10:30:1.54:30。
进一步的,所述白色固体与Pd–C377、甲醇、四氢呋喃(THF)和盐酸溶液的质量体积比为15kg:1.5kg:350L:350L:36L,所述盐酸溶液的浓度为1mol/L。
进一步的,所述洗脱剂由体积比为8:2正己烷和乙酸乙酯组成。
进一步的,所述流动相由体积比为45:55的甲醇和水组成。
进一步的,所述制备型层析柱的型号为JLC1000。
进一步的,所述制备型层析柱的流速为1.4-1.6mL/min
一种盐酸伐昔洛韦制剂,由本发明所述的制备方法制得。
一种盐酸伐昔洛韦片的制备方法,包括以下步骤:
(1)处方:以本发明所述任一项制备方法制得的盐酸伐昔洛韦为主药,以乳糖为稀释剂,以羧甲基淀粉钠、微晶纤维素为崩解剂,以滑石粉为润滑剂,各原料重量份如下:盐酸伐昔洛韦300份、乳糖40-50份、羧甲基淀粉钠10-11份、微晶纤维素10-11份、滑石粉7.0-7.5份;
(2)制备方法:
1)分别将盐酸伐昔洛韦、乳糖、羧甲基淀粉钠及微晶纤维素过80目筛,滑石粉过100目筛,备用;
2)按处方量分别称取盐酸伐昔洛韦、乳糖及羧甲基淀粉钠,混合均匀,备用;
3)加入20%wt乙醇制备软材,过18目筛网进行制粒,湿颗粒于60℃鼓风干燥4小时,得干颗粒;
4)干颗粒用18目筛网整粒,并加入处方量的微晶纤维素及滑石粉,混合均匀;
6)取胃溶型薄膜包衣预混剂及80%wt乙醇,配制成6%w/v的包衣液;
7)调节进风温度为60℃,预热素片温度至35℃~40℃,设定喷液压力为0.3Mpa,包衣液流量为0.3~0.33kg/min,包衣2小时,最后60℃热风干燥10分钟,制得盐酸伐昔洛韦片。
一种盐酸伐昔洛韦胶囊的制备方法,包括以下步骤:
(1)处方:以本发明所述任一项制备方法制得的盐酸伐昔洛韦为主药,以预胶化淀粉为稀释剂,以二氧化硅为助流剂,盐酸伐昔洛韦、预胶化淀粉和二氧化硅的质量比为150:50:2。
(2)制备方法:
1)分别将预胶化淀粉、二氧化硅置于100℃热风干燥1小时,干燥失重应小于4%;
2)分别将盐酸伐昔洛韦、预胶化淀粉过80目筛,二氧化硅过120目筛,备用;3)按处方量分别称取盐酸伐昔洛韦、预胶化淀粉、二氧化硅,混合均匀,备用;
4)根据混合粉末检验结果计算装量,填充于1号硬胶囊;胶囊抛光,铝塑泡罩包装。
与现有技术相比,本发明的有益效果是:
(1)采用本发明制备方法,有效抑制杂质产生,减少或避免阿昔洛韦残留,提高盐酸伐昔洛韦原料药的质量,同时提高其收率,提高生产效率,制备盐酸伐昔洛韦片和盐酸伐昔洛韦胶囊,得到产品质量高,有利于提高药品安全性。
(2)本发明优化原料药生产工艺,通过该方法制备盐酸伐昔洛韦周期短,成本低,大大提高了生产效率和收率。
具体实施方式
为了更好理解本发明技术内容,下面提供具体实施例,对本发明做进一步的说明。
本发明实施例所用的实验方法如无特殊说明,均为常规方法。
本发明实施例所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1盐酸伐昔洛韦的制备
(1)将阿昔洛韦10kg溶解500ml二甲基甲酰胺中,加热至60℃,依次加入N-苄氧羰基-L-缬氨酸15kg、4-二甲胺基吡啶(DMAP)0.77kg、N,N'-二环己基碳酰亚胺(DCC)15kg,保温30min后,放冷至室温搅拌24h,再加入同样量的N-苄氧羰基-L-缬氨酸、DMAP、DCC,室温搅拌48h,得到产物,过滤,收集滤液减压浓缩后得黄色油状物,采用洗脱剂过柱,所述洗脱剂由体积比为8:2正己烷和乙酸乙酯组成,收集白色固体,即2-[(2-氨基-1,6-二氧-6-氧-9H-嘌呤-9-基)甲氧基]乙基-N-苄氧羰基-L-缬氨酸;
(2)取15kg白色固体与1.5kgPd–C377、甲醇350L、四氢呋喃(THF)350L和1M盐酸溶液36L,置高压釜中,于3.4bar条件下催化氢解24h,过滤,收集滤液,经减压浓缩后,再经制备型层析柱制备,型号为JLC1000,流动相由体积比为45:55的甲醇和水组成,流速为1.5mL/min,收集纯化液,减压干燥,得白色粉末状固体,即得盐酸伐昔洛韦,得率为80.2%。
对比例1
与实施例1主要区别在于,步骤(1)中使用洗脱剂为CH2Cl2-CH3OH=10:1。结果显示产物收率明显下降。
对比例2
与实施例1区别在于,步骤(2)未采用制备型层析柱制备。具体为:催化氢解后过滤,浓缩,残渣用50%wt乙醇溶解,加入适量活性炭,70℃搅拌0.5小时,热过滤,滤液冷却析晶,抽滤,65℃减压干燥5小时,得白色粉末状固体。结果显示产物杂质明显增加。
实施例2盐酸伐昔洛韦片的制备
(1)处方:以实施例1制得的盐酸伐昔洛韦为主药,以乳糖为稀释剂,以羧甲基淀粉钠、微晶纤维素为崩解剂,以滑石粉为润滑剂。具体处方量:
盐酸伐昔洛韦片(0.15g)
盐酸伐昔洛韦片(0.3g)
(2)制备方法:
1)分别将盐酸伐昔洛韦、乳糖、羧甲基淀粉钠及微晶纤维素过80目筛,滑石粉过100目筛,备用;
2)按处方量分别称取盐酸伐昔洛韦、乳糖及羧甲基淀粉钠,混合均匀,备用;
3)加入20%wt乙醇制备软材,过18目筛网进行制粒,湿颗粒于60℃鼓风干燥4小时,得干颗粒;
4)干颗粒用18目筛网整粒,并加入处方量的微晶纤维素及滑石粉,混合均匀;
6)取胃溶型薄膜包衣预混剂及80%wt乙醇,配制成6%w/v的包衣液;
7)调节进风温度为60℃,预热素片温度至35℃~40℃,设定喷液压力为0.3Mpa,包衣液流量为0.3~0.33kg/min,包衣2小时,最后60℃热风干燥10分钟,制得盐酸伐昔洛韦片。
实施例3盐酸伐昔洛韦胶囊的制备
(1)处方
以实施例1制得的盐酸伐昔洛韦为主药,以预胶化淀粉为稀释剂,以二氧化硅为助流剂,具体配比如下:
(2)制备方法
1)分别将预胶化淀粉、二氧化硅置于100℃热风干燥1小时,干燥失重应小于4%;
2)分别将盐酸伐昔洛韦、预胶化淀粉过80目筛,二氧化硅过120目筛,备用;3)按处方量分别称取盐酸伐昔洛韦、预胶化淀粉、二氧化硅,混合均匀,备用;
4)根据混合粉末检验结果计算装量,填充于1号硬胶囊;胶囊抛光,铝塑泡罩包装,装盒、装箱。
实施例4
参照《中国药典》2020年版二部,分别对实施例1盐酸伐昔洛韦、实施例2盐酸伐昔洛韦片、实施例3盐酸伐昔洛韦胶囊进行检验,各项检验结果符合药典要求。其中有关物质检查结果如下:
盐酸伐昔洛韦:取含量测定项下的供试品溶液,照含量测定项下的方法,精密量取20μl,注入液相色谱仪,记录色谱图至主峰保留时间的2倍。另取阿昔洛韦对照品约10mg,精密称定,置100ml量瓶中,加0.1mol/L氢氧化钠溶液5ml溶解,加水稀释至刻度,摇匀;精密量取2ml加流动相制成每1ml中含0.2μg阿昔洛韦的对照溶液。同法测定,按外标法计算供试品中阿昔洛韦(C8H11N5O3)的量,应不得过1.5%。在上述供试品溶液的色谱图中如显杂质峰,各杂质峰面积总和不得大于总峰面积的2.0%。
盐酸伐昔洛韦片(0.15g;0.3g):取本品适量,精密称定,加0.01mol/L磷酸二氢钾溶液(用磷酸调节pH值3.0)溶解并稀释制成每lml中约含0.5mg的溶液,作为供试品溶液;精密量取1ml,置200ml量瓶中,用上述0.01mol/L磷酸二氢钾溶液(pH3.0)稀释至刻度,摇匀,作为对照溶液;另取阿昔洛韦对照品约15mg,精密称定,置50ml量瓶中,加0.1mol/L氢氧化钠溶液2ml溶解,再用水稀释至刻度,摇匀,作为阿昔洛韦对照品贮备液;精密量取5ml,置200ml量瓶中,用上述0.01mol/L磷酸二氢钾溶液(pH3.0)稀释至刻度,摇匀,作为阿昔洛韦对照品溶液。照含量测定项下的色谱条件,分别精密量取对照溶液、阿昔洛韦对照品溶液与供试品溶液各20u1,分别注入液相色谱仪,记录色谱图至伐昔洛韦峰保留时间的6倍。供试品溶液色谱图中如有杂质峰,按外标法以峰面积计算含阿昔洛韦不得过1.5%;其他各杂质峰面积的和不得大于对照溶液的主峰面积(0.5%)。
盐酸伐昔洛韦胶囊(0.15g):取装量差异项下的内容物适量(约相当于盐酸伐昔洛韦50mg),置100ml量瓶中,加0.01mol/L磷酸二氢钾溶液(用磷酸调节pH值至3.0)使盐酸伐昔洛韦溶解并稀释至刻度,摇匀,滤过,取续滤液作为供试品溶液。照盐酸伐昔洛韦有关物质项下的方法测定,供试品溶液色谱图中如有杂质峰,按外标法以峰面积计算,含阿昔洛韦不得过盐酸伐昔洛韦标示量的1.5%;其他各杂质峰面积的和不得大于对照溶液主峰面积的2倍(1.0%)。
有关物质结果如下:
阿昔洛韦 | 总杂 | 有机溶剂残留 | |
盐酸伐昔洛韦 | 0.04% | 0.01% | 未检出 |
盐酸伐昔洛韦片(0.15g) | 0.04% | 0.02% | 未检出 |
盐酸伐昔洛韦片(0.3g) | 0.04% | 0.02% | 未检出 |
盐酸伐昔洛韦胶囊(0.15g) | 0.04% | 0.03% | 未检出 |
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种盐酸伐昔洛韦的制备方法,其特征在于,包括以下步骤:
(1)将阿昔洛韦与N-苄氧羰基-L-缬氨酸、4-二甲胺基吡啶、N,N'-二环己基碳酰亚胺反应得到产物,过滤,收集滤液减压浓缩后得黄色油状物,采用洗脱剂过柱,所述洗脱剂由正己烷和乙酸乙酯组成,收集白色固体;
(2)将白色固体与Pd–C377、甲醇、四氢呋喃和盐酸溶液,置高压釜中,催化氢解,过滤,收集滤液,经减压浓缩后,再经制备型层析柱制备,流动相为甲醇和水,收集纯化液,减压干燥,得白色粉末状固体,即得盐酸伐昔洛韦。
2.根据权利要求1所述的盐酸伐昔洛韦的制备方法,其特征在于,所述阿昔洛韦与N-苄氧羰基-L-缬氨酸、4-二甲胺基吡啶、N,N'-二环己基碳酰亚胺的质量比为10∶30∶1.54∶30。
3.根据权利要求1所述的盐酸伐昔洛韦的制备方法,其特征在于,所述白色固体与Pd–C377、甲醇、四氢呋喃和盐酸溶液的质量体积比为15kg∶1.5kg∶350L∶350L∶36L,所述盐酸溶液的浓度为1mol/L。
4.根据权利要求1所述的盐酸伐昔洛韦的制备方法,其特征在于,所述洗脱剂由体积比为8∶2正己烷和乙酸乙酯组成。
5.根据权利要求1所述的盐酸伐昔洛韦的制备方法,其特征在于,所述流动相由体积比为45:55的甲醇和水组成。
6.根据权利要求1所述的盐酸伐昔洛韦的制备方法,其特征在于,所述制备型层析柱的型号为JLC1000。
7.根据权利要求1所述的盐酸伐昔洛韦的制备方法,其特征在于,所述制备型层析柱的流速为1.4-1.6mL/min。
8.一种盐酸伐昔洛韦制剂,其特征在于,由权利要求1-7所述的制备方法制得。
9.一种盐酸伐昔洛韦片的制备方法,其特征在于,包括以下步骤:
(1)处方:
以权利要求1-7所述任一项制备方法制得的盐酸伐昔洛韦为主药,以乳糖为稀释剂,以羧甲基淀粉钠、微晶纤维素为崩解剂,以滑石粉为润滑剂,各原料重量份如下:盐酸伐昔洛韦300份、乳糖40-50份、羧甲基淀粉钠10-11份、微晶纤维素10-11份、滑石粉7.0-7.5份;
(2)制备方法:
1)分别将盐酸伐昔洛韦、乳糖、羧甲基淀粉钠及微晶纤维素过80目筛,滑石粉过100目筛,备用;
2)按处方量分别称取盐酸伐昔洛韦、乳糖及羧甲基淀粉钠,混合均匀,备用;
3)加入20%wt乙醇制备软材,过18目筛网进行制粒,湿颗粒于60℃鼓风干燥4小时,得干颗粒;
4)干颗粒用18目筛网整粒,并加入处方量的微晶纤维素及滑石粉,混合均匀;
6)取胃溶型薄膜包衣预混剂及80%wt乙醇,配制成6%w/v的包衣液;
7)调节进风温度为60℃,预热素片温度至35℃~40℃,设定喷液压力为0.3Mpa,包衣液流量为0.3~0.33kg/min,包衣2小时,最后60℃热风干燥10分钟,制得盐酸伐昔洛韦片。
10.一种盐酸伐昔洛韦胶囊的制备方法,其特征在于,包括以下步骤:
(1)处方:
以权利要求1-7所述任一项制备方法制得的盐酸伐昔洛韦为主药,以预胶化淀粉为稀释剂,以二氧化硅为助流剂,盐酸伐昔洛韦、预胶化淀粉和二氧化硅的质量比为150∶50∶2。
(2)制备方法:
1)分别将预胶化淀粉、二氧化硅置于100℃热风干燥1小时,干燥失重应小于4%;
2)分别将盐酸伐昔洛韦、预胶化淀粉过80目筛,二氧化硅过120目筛,备用;
3)按处方量分别称取盐酸伐昔洛韦、预胶化淀粉、二氧化硅,混合均匀,备用;
4)根据混合粉末检验结果计算装量,填充于1号硬胶囊;胶囊抛光,铝塑泡罩包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210189997.4A CN114621227A (zh) | 2022-02-28 | 2022-02-28 | 一种盐酸伐昔洛韦、制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210189997.4A CN114621227A (zh) | 2022-02-28 | 2022-02-28 | 一种盐酸伐昔洛韦、制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114621227A true CN114621227A (zh) | 2022-06-14 |
Family
ID=81899435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210189997.4A Pending CN114621227A (zh) | 2022-02-28 | 2022-02-28 | 一种盐酸伐昔洛韦、制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114621227A (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1612878A (zh) * | 2001-11-14 | 2005-05-04 | 特瓦制药工业有限公司 | 伐昔洛韦的合成与纯化 |
CN1903854A (zh) * | 2006-08-09 | 2007-01-31 | 丽珠医药集团股份有限公司 | 一种合成盐酸伐昔洛韦的方法 |
CN101002781A (zh) * | 2006-01-19 | 2007-07-25 | 上海秀新臣邦医药科技有限公司 | 盐酸伐昔洛韦片及其制备方法 |
CN103462918A (zh) * | 2013-09-22 | 2013-12-25 | 南京正亮医药科技有限公司 | 一种盐酸伐昔洛韦片剂及其制备方法 |
CN103479599A (zh) * | 2013-09-18 | 2014-01-01 | 南京正亮医药科技有限公司 | 一种盐酸伐昔洛韦胶囊制剂及其制备方法 |
CN104188928A (zh) * | 2014-09-17 | 2014-12-10 | 山东新时代药业有限公司 | 一种盐酸伐昔洛韦片剂及其制备方法 |
CN106632335A (zh) * | 2016-12-27 | 2017-05-10 | 河南康达制药有限公司 | 一种盐酸伐昔洛韦的制备方法 |
CN109651371A (zh) * | 2018-12-31 | 2019-04-19 | 辰欣药业股份有限公司 | 一种盐酸伐昔洛韦的制备方法 |
CN109662951A (zh) * | 2018-12-31 | 2019-04-23 | 辰欣药业股份有限公司 | 一种高生物利用度的盐酸伐昔洛韦分散片及其制备工艺 |
CN110279667A (zh) * | 2019-07-30 | 2019-09-27 | 珠海润都制药股份有限公司 | 一种盐酸伐昔洛韦片及其制备方法 |
CN112691085A (zh) * | 2020-12-29 | 2021-04-23 | 澳美制药(苏州)有限公司 | 盐酸伐昔洛韦片及其制备方法 |
-
2022
- 2022-02-28 CN CN202210189997.4A patent/CN114621227A/zh active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1612878A (zh) * | 2001-11-14 | 2005-05-04 | 特瓦制药工业有限公司 | 伐昔洛韦的合成与纯化 |
CN101002781A (zh) * | 2006-01-19 | 2007-07-25 | 上海秀新臣邦医药科技有限公司 | 盐酸伐昔洛韦片及其制备方法 |
CN1903854A (zh) * | 2006-08-09 | 2007-01-31 | 丽珠医药集团股份有限公司 | 一种合成盐酸伐昔洛韦的方法 |
CN103479599A (zh) * | 2013-09-18 | 2014-01-01 | 南京正亮医药科技有限公司 | 一种盐酸伐昔洛韦胶囊制剂及其制备方法 |
CN103462918A (zh) * | 2013-09-22 | 2013-12-25 | 南京正亮医药科技有限公司 | 一种盐酸伐昔洛韦片剂及其制备方法 |
CN104188928A (zh) * | 2014-09-17 | 2014-12-10 | 山东新时代药业有限公司 | 一种盐酸伐昔洛韦片剂及其制备方法 |
CN106632335A (zh) * | 2016-12-27 | 2017-05-10 | 河南康达制药有限公司 | 一种盐酸伐昔洛韦的制备方法 |
CN109651371A (zh) * | 2018-12-31 | 2019-04-19 | 辰欣药业股份有限公司 | 一种盐酸伐昔洛韦的制备方法 |
CN109662951A (zh) * | 2018-12-31 | 2019-04-23 | 辰欣药业股份有限公司 | 一种高生物利用度的盐酸伐昔洛韦分散片及其制备工艺 |
CN110279667A (zh) * | 2019-07-30 | 2019-09-27 | 珠海润都制药股份有限公司 | 一种盐酸伐昔洛韦片及其制备方法 |
CN112691085A (zh) * | 2020-12-29 | 2021-04-23 | 澳美制药(苏州)有限公司 | 盐酸伐昔洛韦片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104788438B (zh) | 恩格列净b晶型及其制备 | |
MXPA06008197A (es) | Proceso para la preparacion de clorhidrato de valaciclovir. | |
US9169257B2 (en) | Crystal forms of adefovir dipivoxil and processes for preparing the same | |
CN106749101A (zh) | 一种盐酸地芬尼多的制备方法 | |
CN114621227A (zh) | 一种盐酸伐昔洛韦、制剂及其制备方法 | |
CN113277971A (zh) | 一种格列美脲杂质及其制备方法 | |
CN113004244A (zh) | 一种曲格列汀杂质及其制备方法和用途 | |
CN114507202B (zh) | 一种桑辛素类化合物及其制备方法与应用 | |
CN114174264B (zh) | 一种甲磺酸仑伐替尼晶型xi及其制备方法 | |
WO2011095985A2 (en) | Rasagiline salts and processes for the preparation thereof | |
CN104447689B (zh) | 来那度胺的晶型及其制备方法 | |
CN109776543A (zh) | 依鲁替尼盐、其晶体、制备方法、药物组合物及应用 | |
CN110128359B (zh) | 一种尿酸转运体1抑制剂的晶体及其制备方法和用途 | |
CN103554057B (zh) | 曲美他嗪衍生物及其制备方法 | |
EP3604284B1 (en) | Crystalline eltrombopag monoethanolamine salt form d | |
CN113646303A (zh) | Fak抑制剂的盐和晶型 | |
CN114524746B (zh) | 拉考沙胺晶型的制备方法 | |
CN104387335B (zh) | 拉莫三嗪与2,2’-联吡啶药物共晶及其制备方法 | |
CN114920689A (zh) | 一种瑞戈非尼中间体的制备方法 | |
CN115403538B (zh) | 一种依帕司他晶型及其制备方法和应用 | |
CN114349770B (zh) | 一种凝血FXa抑制剂的制备方法 | |
EP4230625A1 (en) | Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof | |
EP4056182A1 (en) | Crystal form of aprocitentan, preparation method therefor and use thereof | |
CN108341818A (zh) | 巴瑞克替尼及其磷酸盐的新晶型及其制备方法 | |
CN107141328A (zh) | 一种单磷酸阿糖腺苷新晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |